LT3288944T - Imidazopirazinonai, kaip pde1 inhibitoriai - Google Patents

Imidazopirazinonai, kaip pde1 inhibitoriai

Info

Publication number: LT3288944T
Authority: LT; Lithuania
Prior art keywords: imidazopyrazinones; pde1; inhibitors
Prior art date: 2015-04-30

Application number

LTEP16720101.1T

Other languages

English (en)

Inventor

Jan Kehler

Lars Rasmussen

Morten LANGGÅRD

Mikkel JESSING

Paulo Vital

Karsten Juhl

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-30

Filing date

2016-04-29

Publication date

2019-07-25

2016-04-29 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2019-07-25 Publication of LT3288944T publication Critical patent/LT3288944T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP16720101.1T 2015-04-30 2016-04-29 Imidazopirazinonai, kaip pde1 inhibitoriai LT3288944T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA201500261		2015-04-30
DKPA201500666		2015-10-29
DKPA201600202		2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en)	2015-04-30	2016-04-29	Imidazopyrazinones as pde1 inhibitors

Publications (1)

Publication Number	Publication Date
LT3288944T true LT3288944T (lt)	2019-07-25

Family

ID=55910242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16720101.1T LT3288944T (lt)	2015-04-30	2016-04-29	Imidazopirazinonai, kaip pde1 inhibitoriai

Country Status (42)

Country	Link
US (4)	US20160318939A1 (lt)
EP (1)	EP3288944B1 (lt)
JP (1)	JP6663930B2 (lt)
KR (1)	KR102605759B1 (lt)
CN (1)	CN107531714B (lt)
AU (1)	AU2016256573B2 (lt)
BR (1)	BR112017023182B1 (lt)
CA (1)	CA2983563A1 (lt)
CL (1)	CL2017002719A1 (lt)
CO (1)	CO2017010399A2 (lt)
CY (1)	CY1121806T1 (lt)
DK (1)	DK3288944T3 (lt)
DO (1)	DOP2017000254A (lt)
EA (1)	EA031946B1 (lt)
EC (1)	ECSP17072228A (lt)
ES (1)	ES2735422T3 (lt)
GE (1)	GEP20207058B (lt)
GT (1)	GT201700223A (lt)
HK (1)	HK1252098B (lt)
HR (1)	HRP20191180T1 (lt)
HU (1)	HUE044244T2 (lt)
IL (1)	IL255316B (lt)
JO (1)	JO3627B1 (lt)
LT (1)	LT3288944T (lt)
MA (1)	MA41977B1 (lt)
ME (1)	ME03414B (lt)
MX (1)	MX2017013785A (lt)
MY (1)	MY182382A (lt)
PE (1)	PE20180121A1 (lt)
PH (1)	PH12017501990B1 (lt)
PL (1)	PL3288944T3 (lt)
PT (1)	PT3288944T (lt)
RS (1)	RS59051B1 (lt)
RU (1)	RU2712219C2 (lt)
SG (1)	SG11201708822PA (lt)
SI (1)	SI3288944T1 (lt)
SM (1)	SMT201900393T1 (lt)
TN (1)	TN2017000428A1 (lt)
TW (1)	TWI695838B (lt)
UA (1)	UA123050C2 (lt)
WO (1)	WO2016174188A1 (lt)
ZA (1)	ZA201706847B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201629064A (zh)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (en)	2016-10-18	2023-12-06	H. Lundbeck A/S	Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
US10912773B2 (en)	2016-10-28	2021-02-09	H. Lundbeck A/S	Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
US10905688B2 (en) *	2016-10-28	2021-02-02	H. Lundbeck A/S	Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
JOP20190126A1 (ar)	2016-12-22	2019-05-28	H Lundbeck As	بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
MX2019007803A (es)	2016-12-28	2019-08-29	Dart Neuroscience Llc	Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
DK3717488T3 (da)	2017-11-27	2021-12-13	Dart Neuroscience Llc	Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
AR113926A1 (es) *	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh)	2017-12-20	2023-10-27	H.隆德贝克有限公司	作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
IT202200024948A1 (it) *	2022-12-05	2024-06-05	Angelini Pharma S P A	Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB973361A (en)	1960-05-11	1964-10-28	Ciba Ltd	Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de)	1997-03-11	1998-09-17	Bayer Ag	1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
EP1626971B1 (de)	2003-05-09	2011-08-10	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
SI1740591T1 (sl) *	2004-04-02	2009-12-31	Osi Pharm Inc	Heterobiciklični inhibitorji protein-kinaze, substituirani s 6,6-bicikličnim obročem
EP1828192B1 (en) *	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007025103A2 (en) *	2005-08-23	2007-03-01	Intra-Cellular Therapies, Inc.	Organic compounds for treating reduced dopamine receptor signalling activity
US8012936B2 (en)	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
JP5837278B2 (ja)	2006-12-05	2015-12-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
PL2152712T3 (pl)	2007-05-11	2012-05-31	Pfizer	Związki aminoheterocykliczne
CA2706986A1 (en)	2007-11-30	2009-06-04	Elbion Gmbh	Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (es) *	2008-09-08	2011-07-15	Boehringer Ingelheim Int	Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
MA32941B1 (fr) *	2008-12-06	2012-01-02	Intra Cellular Therapies Inc	Composes organiques
TWI404721B (zh) *	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
US8748386B2 (en)	2009-06-10	2014-06-10	New York University	Immunological targeting of pathological Tau proteins
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
ME02352B (me)	2010-08-12	2016-06-20	Lilly Co Eli	PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
ES2610360T3 (es) *	2010-09-20	2017-04-27	Ironwood Pharmaceuticals, Inc.	Compuestos de imidazotriazinona
EP2619204A4 (en)	2010-09-21	2014-08-27	Merck Sharp & Dohme	TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
JO3089B1 (ar)	2010-11-19	2017-03-15	H Lundbeck As	مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en)	2011-04-08	2012-10-11	H. Lundbeck A/S	ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organic compounds
SG11201502728WA (en) *	2011-10-10	2015-05-28	Lundbeck & Co As H	Pde9i with imidazo pyrazinone backbone
WO2013110768A1 (en)	2012-01-26	2013-08-01	H. Lundbeck A/S	Pde9 inhibitors with imidazo triazinone backbone
JP2013166727A (ja)	2012-02-16	2013-08-29	Dainippon Sumitomo Pharma Co Ltd	ジヒドロイミダゾピラジノン誘導体
SG10201703253XA (en)	2012-06-18	2017-06-29	Dart Neuroscience (Cayman) Ltd	Substituted pyridine azolopyrimidine-5-(6h)-one compounds
JP6437519B2 (ja)	2013-03-15	2018-12-12	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
JP5783297B2 (ja)	2013-08-06	2015-09-24	株式会社デンソー	力学量センサ
MA39225A1 (fr)	2014-02-19	2017-04-28	H Lundbeck As	2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
JP5797815B1 (ja)	2014-06-27	2015-10-21	細田建設株式会社	後施工アンカー及びその施工方法
US20160083391A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic piperazine derivative
US20160083400A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic guanidine derivative
WO2016042775A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic derivative
TW201629064A (zh)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	作爲ｐｄｅ１抑制劑之三唑並吡酮
MA40941A (fr)	2014-11-10	2017-09-19	H Lundbeck As	2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es)	2014-11-10	2018-02-01	H Lundbeck As	2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar)	2014-11-10	2020-07-05	H Lundbeck As	2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
WO2016147659A1 (en)	2015-03-16	2016-09-22	Sumitomo Dainippon Pharma Co., Ltd.	Bicyclic imidazolo derivative
US20160311831A1 (en)	2015-04-22	2016-10-27	H. Lundbeck A/S	Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017025559A1 (en)	2015-08-12	2017-02-16	H. Lundbeck A/S	2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
AR107456A1 (es)	2016-02-12	2018-05-02	Lilly Co Eli	Inhibidor de pde1
TWI729109B (zh)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (en)	2016-10-18	2023-12-06	H. Lundbeck A/S	Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
US10905688B2 (en)	2016-10-28	2021-02-02	H. Lundbeck A/S	Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
US10912773B2 (en)	2016-10-28	2021-02-09	H. Lundbeck A/S	Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors

2016
- 2016-04-26 JO JOP/2016/0081A patent/JO3627B1/ar active
- 2016-04-27 TW TW105113074A patent/TWI695838B/zh active
- 2016-04-29 RU RU2017137514A patent/RU2712219C2/ru active
- 2016-04-29 SI SI201630319T patent/SI3288944T1/sl unknown
- 2016-04-29 EA EA201792157A patent/EA031946B1/ru not_active IP Right Cessation
- 2016-04-29 CA CA2983563A patent/CA2983563A1/en active Pending
- 2016-04-29 PT PT16720101T patent/PT3288944T/pt unknown
- 2016-04-29 MY MYPI2017001597A patent/MY182382A/en unknown
- 2016-04-29 AU AU2016256573A patent/AU2016256573B2/en active Active
- 2016-04-29 RS RS20190893A patent/RS59051B1/sr unknown
- 2016-04-29 KR KR1020177030665A patent/KR102605759B1/ko active IP Right Grant
- 2016-04-29 CN CN201680023903.9A patent/CN107531714B/zh active Active
- 2016-04-29 TN TNP/2017/000428A patent/TN2017000428A1/en unknown
- 2016-04-29 MA MA41977A patent/MA41977B1/fr unknown
- 2016-04-29 WO PCT/EP2016/059583 patent/WO2016174188A1/en active Application Filing
- 2016-04-29 LT LTEP16720101.1T patent/LT3288944T/lt unknown
- 2016-04-29 US US15/142,116 patent/US20160318939A1/en not_active Abandoned
- 2016-04-29 HU HUE16720101 patent/HUE044244T2/hu unknown
- 2016-04-29 PL PL16720101T patent/PL3288944T3/pl unknown
- 2016-04-29 MX MX2017013785A patent/MX2017013785A/es active IP Right Grant
- 2016-04-29 PE PE2017002342A patent/PE20180121A1/es unknown
- 2016-04-29 BR BR112017023182-4A patent/BR112017023182B1/pt active IP Right Grant
- 2016-04-29 GE GEAP201614615A patent/GEP20207058B/en unknown
- 2016-04-29 SM SM20190393T patent/SMT201900393T1/it unknown
- 2016-04-29 SG SG11201708822PA patent/SG11201708822PA/en unknown
- 2016-04-29 DK DK16720101.1T patent/DK3288944T3/da active
- 2016-04-29 JP JP2017556677A patent/JP6663930B2/ja active Active
- 2016-04-29 UA UAA201710625A patent/UA123050C2/uk unknown
- 2016-04-29 EP EP16720101.1A patent/EP3288944B1/en active Active
- 2016-04-29 ES ES16720101T patent/ES2735422T3/es active Active
- 2016-04-29 ME MEP-2019-186A patent/ME03414B/me unknown
2017
- 2017-06-06 US US15/615,380 patent/US10011606B2/en active Active
- 2017-10-10 ZA ZA2017/06847A patent/ZA201706847B/en unknown
- 2017-10-12 CO CONC2017/0010399A patent/CO2017010399A2/es unknown
- 2017-10-24 GT GT201700223A patent/GT201700223A/es unknown
- 2017-10-26 CL CL2017002719A patent/CL2017002719A1/es unknown
- 2017-10-27 EC ECIEPI201772228A patent/ECSP17072228A/es unknown
- 2017-10-29 IL IL255316A patent/IL255316B/en unknown
- 2017-10-30 DO DO2017000254A patent/DOP2017000254A/es unknown
- 2017-10-30 PH PH12017501990A patent/PH12017501990B1/en unknown
2018
- 2018-06-07 US US16/002,116 patent/US10858362B2/en active Active
- 2018-09-05 HK HK18111408.3A patent/HK1252098B/zh unknown
2019
- 2019-07-01 HR HRP20191180TT patent/HRP20191180T1/hr unknown
- 2019-07-15 CY CY20191100751T patent/CY1121806T1/el unknown
2020
- 2020-10-26 US US17/079,951 patent/US11472810B2/en active Active

Also Published As

Publication number	Publication date
MA41977A (fr)	2018-07-23
CA2983563A1 (en)	2016-11-03
HK1252098B (zh)	2020-02-07
US20210238182A1 (en)	2021-08-05
RU2017137514A (ru)	2019-05-31
EP3288944A1 (en)	2018-03-07
ECSP17072228A (es)	2018-02-28
GT201700223A (es)	2018-12-19
SG11201708822PA (en)	2017-11-29
PH12017501990B1 (en)	2021-01-13
CO2017010399A2 (es)	2018-01-05
US20170291903A1 (en)	2017-10-12
ES2735422T3 (es)	2019-12-18
US11472810B2 (en)	2022-10-18
US20190062335A1 (en)	2019-02-28
TW201700477A (zh)	2017-01-01
GEP20207058B (en)	2020-01-27
IL255316B (en)	2021-10-31
RS59051B1 (sr)	2019-08-30
RU2017137514A3 (lt)	2019-07-17
HUE044244T2 (hu)	2019-10-28
SMT201900393T1 (it)	2019-09-09
PT3288944T (pt)	2019-07-19
CN107531714B (zh)	2019-07-19
JP6663930B2 (ja)	2020-03-13
BR112017023182B1 (pt)	2023-10-31
TWI695838B (zh)	2020-06-11
JO3627B1 (ar)	2020-08-27
ZA201706847B (en)	2019-01-30
IL255316A0 (en)	2017-12-31
RU2712219C2 (ru)	2020-01-27
DOP2017000254A (es)	2018-01-15
CY1121806T1 (el)	2020-07-31
US10858362B2 (en)	2020-12-08
WO2016174188A1 (en)	2016-11-03
EA031946B1 (ru)	2019-03-29
CN107531714A (zh)	2018-01-02
SI3288944T1 (sl)	2019-08-30
MA41977B1 (fr)	2019-08-30
KR102605759B1 (ko)	2023-11-23
AU2016256573A1 (en)	2017-12-14
EP3288944B1 (en)	2019-06-12
MY182382A (en)	2021-01-22
BR112017023182A2 (lt)	2018-10-02
DK3288944T3 (da)	2019-07-22
JP2018514552A (ja)	2018-06-07
MX2017013785A (es)	2018-03-27
PH12017501990A1 (en)	2018-03-26
US20160318939A1 (en)	2016-11-03
PL3288944T3 (pl)	2019-11-29
HK1252098A1 (zh)	2019-05-17
CL2017002719A1 (es)	2018-04-20
AU2016256573B2 (en)	2019-11-21
TN2017000428A1 (en)	2019-04-12
KR20170140216A (ko)	2017-12-20
UA123050C2 (uk)	2021-02-10
PE20180121A1 (es)	2018-01-18
HRP20191180T1 (hr)	2019-10-04
EA201792157A1 (ru)	2018-03-30
US10011606B2 (en)	2018-07-03
ME03414B (me)	2020-01-20

Publication	Publication Date	Title
CY2024003I2 (el)	2024-09-20	Ενωσεις χρησιμες ως αναστολεις κινασης
LT3303334T (lt)	2021-07-12	Tirozinkinazės inhibitoriai
EP3377059A4 (en)	2019-03-20	INHIBITORS OF CXCR2
HK1249097A1 (zh)	2018-10-26	作為pde1抑制劑的咪唑並三嗪酮
LT3371190T (lt)	2022-08-10	Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
LT3105226T (lt)	2019-11-11	Ciklopropilaminai, kaip lsd1 inhibitoriai
MA44474A (fr)	2019-01-30	Nouveaux inhibiteurs de la ferroportine
EP3313828A4 (en)	2019-01-09	METALLO-BETA-Lactamase INHIBITORS
DK3072835T3 (da)	2019-07-29	Fremgangsmåde til fremføring
LT3288944T (lt)	2019-07-25	Imidazopirazinonai, kaip pde1 inhibitoriai
BR112017000042A2 (pt)	2018-07-17	inibidores de desmetilase-1 lisina-específica
MA44006A (fr)	2021-04-14	Inhibiteur pde1
PL3258674T3 (pl)	2019-02-28	Wybór procedury ukrywania straty pakietu
EP3386505A4 (en)	2019-06-26	AZA-BENZIMIDAZOLINHIBITORS OF PAD4
DK3116475T3 (da)	2020-12-07	Dopa-decarboxylasehæmmersammensætninger
DK3341379T3 (da)	2019-12-02	EZH2-hæmmere
MA43367A (fr)	2018-10-10	Inhibiteurs de métallo-bêta-lactamases
DK3114120T3 (da)	2019-05-20	Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3283210T3 (da)	2021-11-22	Fremgangsmåde
EP3328991A4 (en)	2019-04-10	BIOSYNTHESIS OF POLYCETIDES
DK3331498T3 (da)	2020-06-15	Nasalsammensætning
LT3319970T (lt)	2019-11-11	Pirido-oksazinono dariniai kaip tnap inhibitoriai
LT3126354T (lt)	2020-03-25	Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai
CL2016001959A1 (es)	2017-02-24	Hexahidrofuropirroles como inhibidores de pde1
ES1137506Y (es)	2015-06-10	Helice reductora de perdidas